ArticleACS applied materials & interfaces2023
High-Fidelity Extrusion Bioprinting of Low-Printability Polymers Using Carbopol as a Rheology Modifier.
Article in ACS applied materials & interfaces, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- A Systematic Study of GelMA-Carbopol Bioinks for High-Fidelity Extrusion 3D Bioprinting at Physiological Temperatures.Advanced healthcare materials · 2026Article
- Support-Enabled 3D Printing of Complex Anisotropic Hydrogel Structures Using Cellulose-Based Inks: Pathways Toward Biomimetic Human Aorta Models.ACS biomaterials science & engineering · 2026Article
- High-yield cell-derived extracellular matrix bioink via macromolecular crowding for versatile 3D bioprinting.Materials today. Bio · 2026Article
- 3D-Printed Mucoadhesive Hydrogel Buccal Films Based on HPMC and Carbopol Bioinks Incorporating Cyclodextrin-Cannabinoid Complexes and Terpenes.Gels (Basel, Switzerland) · 2026Article
- Unconventional bioprinting modalities for advanced tissue biofabrication.Biomaterials · 2026Review
- Quantitative Assessment of Hydrogel Printability in Extrusion Bioprinting.Gels (Basel, Switzerland) · 2026Review
- Rheological, Structural, and Biological Trade-Offs in Bioink Design for 3D Bioprinting.Gels (Basel, Switzerland) · 2025Review
- Advances in 3D-printed scaffold technologies for bone defect repair: materials, biomechanics, and clinical prospects.Biomedical engineering online · 2025Review
- A Low-Cost, Open-Source 3D Printer for Multimaterial and High-Throughput Direct Ink Writing of Soft and Living Materials.Advanced materials (Deerfield Beach, Fla.) · 2025Article
- Photocrosslinkable Biomaterials for 3D Bioprinting: Mechanisms, Recent Advances, and Future Prospects.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extrusion three-dimensional (3D) bioprinting is a promising technology with many applications in the biomedical and tissue engineering fields. One of the key limitations for the widespread use of this technology is the narrow window of printability that results from the need to have bioinks with rheological properties that allow the extrusion of continuous filaments while maintaining high cell viability within the materials during and after printing. In this work, we use Carbopol (CBP) as rheology modifier for extrusion printing of biomaterials that are typically nonextrudable or present low printability. We show that low concentrations of CBP can introduce the desired rheological properties for a wide range of formulations, allowing the use of polymers with different cross-linking mechanisms and the introduction of additives and cells. To explore the opportunities and limitations of CBP as a rheology modifier, we used ink formulations based on poly(ethylene glycol)diacrylate with extrusion 3D printing to produce soft, yet stable, hydrogels with tunable mechanical properties. Cell-laden constructs made with such inks presented high viability for cells seeded on top of cross-linked materials and cells incorporated within the bioink during printing, showing that the materials are noncytotoxic and the printed structures do not degrade for up to 14 days. To our knowledge, this is the first report of the use of CBP-containing bioinks to 3D-print complex cell-laden structures that are stable for days and present high cell viability. The use of CBP to obtain highly printable inks can accelerate the evolution of extrusion 3D bioprinting by guaranteeing the required rheological properties and expanding the number of materials that can be successfully printed. This will allow researchers to develop and optimize new bioinks focusing on the biochemical, cellular, and mechanical requirements of the targeted applications rather than the rheology needed to achieve good printability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.